Review
Pharmacology & Pharmacy
Faiza Naseer, Tahir Ahmad, Kousain Kousar, Sadia Anjum
Summary: This article discusses advanced therapeutic regimens for prostatic adenocarcinoma (PaC), including chemotherapy, hormonal therapy, immunotherapy, and gene therapy. These therapies target the androgen receptors and inhibit steroidogenic enzymes to reduce testosterone and dihydrotestosterone levels. Targeting DNA damage repair pathways is also a focus to overcome resistance mechanisms in the treatment of mCRPC.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Janney Z. Wang, Vivian Lin, Elsa Toumi, Ke Wang, Hong Zhu, R. Max Conway, Michele C. Madigan, Michael Murray, Svetlana Cherepanoff, Fanfan Zhou, Wenying Shu
Summary: Uveal melanoma is the most common primary intraocular malignancy in adults, with important cytogenetic and genetic risk factors including chromosome 3 monosomy and mutations in GNAQ/GNA11 genes. While most primary UMs are treated with radiotherapy, enucleation may be necessary for large tumours. Despite efforts to utilize targeted therapies and immunotherapies developed for other cancers, effective treatments for UM remain limited. New approaches, such as proteasomal and histone deacetylase inhibitors, show potential for treating UM, but further research and individualized tumor profiling are needed to improve outcomes.
Review
Medicine, General & Internal
Brendan D. Curti, Mark B. Faries
Summary: Improvements in management have led to increased survival rates for melanoma, with advances such as sentinel-node sampling and targeted therapy reducing morbidity and enhancing treatment outcomes for advanced disease.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Oncology
Marta Fudalej, Daria Kwasniewska, Pawel Nurzynski, Anna Badowska-Kozakiewicz, Dominika Mekal, Aleksandra Czerw, Katarzyna Sygit, Andrzej Deptala
Summary: Poor prognosis of pancreatic cancer (PC) is associated with several factors, such as diagnosis at an advanced stage, early distant metastases, and remarkable resistance to most conventional treatment options. The pathogenesis of PC seems to be significantly more complicated than originally assumed. To develop effective treatment schemes prolonging patient survival, a multidirectional approach encompassing different aspects of the cancer is needed. Further studies bringing together different therapeutic strategies are required. This review provides an overview of new or emerging therapeutic strategies for the more effective management of metastatic PC.
Review
Oncology
Charlise Basson, June Cheptoo Serem, Priyesh Bipath, Yvette Nkondo Hlophe
Summary: This article discusses the pathological characteristics of cutaneous melanoma, which is becoming increasingly prevalent, as well as the use of chemotherapy in the treatment of cutaneous melanoma. It is found that the activation of chemokine axes plays an important role in the metastasis of melanoma, so intervention targeting these axes can be considered in the treatment of melanoma. Experimental results have shown that targeting chemokine axes can inhibit the migration, proliferation, and survival of tumor cells, thereby slowing down the metastasis and progression of melanoma.
Review
Cell Biology
Elisabetta Fratta, Giorgio Giurato, Roberto Guerrieri, Francesca Colizzi, Jessica Dal Col, Alessandro Weisz, Agostino Steffan, Barbara Montico
Summary: Autophagy plays a crucial role in cutaneous melanoma, but its impact on tumor development remains controversial. Of particular interest, autophagy is increased in BRAF-mutant melanoma and impairs targeted therapy. Moreover, recent studies have highlighted the involvement of mitophagy and secretory autophagy in BRAF-mutant melanoma.
CELL DEATH DISCOVERY
(2023)
Article
Multidisciplinary Sciences
Patricia M. LoRusso, Aleksandar Sekulic, Jeffrey A. Sosman, Winnie S. Liang, John Carpten, David W. Craig, David B. Solit, Alan H. Bryce, Jeffrey A. Kiefer, Jessica Aldrich, Sara Nasser, Rebecca Halperin, Sara A. Byron, Mary Jo Pilat, Scott A. Boerner, Diane Durecki, William P. D. Hendricks, Daniel Enriquez, Tyler Izatt, Jonathan Keats, Christophe Legendre, Svetomir N. Markovic, Amy Weise, Fatima Naveed, Jessica Schmidt, Gargi D. Basu, Shobana Sekar, Jonathan Adkins, Erica Tassone, Karthigayini Sivaprakasam, Victoria Zismann, Valerie S. Calvert, Emanuel F. Petricoin, Leslie Anne Fecher, Christopher Lao, J. Paul Eder, Nicholas J. Vogelzang, Jane Perlmutter, Mark Gorman, Barbara Manica, Lisa Fox, Nicholas Schork, Daniel Zelterman, Michelle DeVeaux, Richard W. Joseph, C. Lance Cowey, Jeffrey M. Trent
Summary: Combination BRAF and MEK inhibitors show high efficacy in treating cutaneous metastatic melanomas with BRAF(V600) mutations, but targeted agents are less effective for BRAF(V600)wild-type metastatic melanomas. The study highlights the importance of comprehensive genomic profiling and the need for further development of molecularly-driven therapies for metastatic melanomas.
Article
Biochemistry & Molecular Biology
Paula Colon-Bolea, Rocio Garcia-Gomez, Berta Casar
Summary: Metastasis is a complicated process in which cancer cells escape from the primary tumor and spread to distant organs. RAC1, a member of the RHO family, plays a crucial role in cancer migration, invasion, angiogenesis, and metastasis. Targeting RAC1 is seen as a promising strategy for treating metastatic cutaneous melanoma.
Review
Biochemistry & Molecular Biology
Fabiana Tortora, Evelina La Civita, Pankaj Trivedi, Ferdinando Febbraio, Daniela Terracciano, Amelia Cimmino
Summary: Renal cell carcinoma, bladder cancer, and prostate cancer are the most common genitourinary tumors. Recent advancements in understanding oncogenic factors and molecular mechanisms have greatly improved their treatment and diagnosis. Non-coding RNAs, such as microRNAs, long non-coding RNAs, and circular RNAs, have been found to play important roles in the occurrence and progression of genitourinary cancers. Interactions of DNA, protein, and RNA with lncRNAs and other biological macromolecules contribute to cancer phenotypes. This review focuses on the mechanisms of abnormal lncRNA expression in genitourinary tumors and their potential applications in diagnostics, prognosis, and treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Jenny J. Li, Jane E. Rogers, Kohei Yamashita, Rebecca E. Waters, Mariela Blum Murphy, Jaffer A. Ajani
Summary: Gastroesophageal cancers are aggressive malignancies with poor prognosis. Different subtypes of these cancers have distinct molecular biology, which affects available treatment targets and response. Multimodality therapy is needed for localized cases, and treatment decisions require multidisciplinary discussions.
Review
Radiology, Nuclear Medicine & Medical Imaging
Pietro Valerio Foti, Mario Travali, Renato Farina, Stefano Palmucci, Corrado Spatola, Rocco Luca Emanuele Liardo, Roberto Milazzotto, Luigi Raffaele, Vincenzo Salamone, Rosario Caltabiano, Giuseppe Broggi, Lidia Puzzo, Andrea Russo, Michele Reibaldi, Antonio Longo, Paolo Vigneri, Teresio Avitabile, Giovani Carlo Ettorre, Antonio Basile
Summary: The therapy for uveal melanoma aims to preserve eye function and prevent metastasis, and requires personalized treatment strategies combining various techniques. Plaque brachytherapy is commonly used for smaller melanomas, while proton beam therapy is for larger tumors with complex shapes. Enucleation is reserved for advanced cases. Radiation therapy complications are common and varied, dependent on tumor characteristics. The review summarizes diagnostic methods, therapeutic options, and potential ocular complications for radiologists to consider.
INSIGHTS INTO IMAGING
(2021)
Article
Biochemistry & Molecular Biology
Anne Uebel, Stefanie Kewitz-Hempel, Edith Willscher, Kathleen Gebhardt, Cord Sunderkoetter, Dennis Gerloff
Summary: Activating BRAF mutations are present in 50-60% of malignant melanomas. Inhibiting EZH2 or its downstream target PLK1, in combination with BRAF inhibitors, may provide potential novel therapeutic options for melanomas with BRAF mutations.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Fulvio Borella, Stefano Fucina, Luca Mangherini, Stefano Cosma, Andrea Roberto Carosso, Jessica Cusato, Paola Cassoni, Luca Bertero, Dionyssios Katsaros, Chiara Benedetto
Summary: Epithelial ovarian cancer (EOC) is a leading cause of cancer-related death in women, and its treatment remains challenging with poor survival rates. While the role of hormone receptors (HRs) in EOC has been actively explored, the use of hormone therapy (HT) in treating these tumors is still not well-established. Available data mostly come from retrospective series and small early clinical trials, suggesting that HT may be beneficial in adjuvant therapy, maintenance therapy, or in cases of recurrent disease, particularly for certain subtypes of EOC.
Review
Oncology
Marta Malczewska, Kamil Kosmider, Kinga Bednarz, Katarzyna Ostapinska, Monika Lejman, Joanna Zawitkowska
Summary: Acute lymphoblastic leukemia is the most common blood cancer in pediatric patients. Despite significant progress in treatment, some patients cannot be saved. Conventional methods of treatment carry high toxicities, reducing effectiveness and sometimes leading to death. Novel treatments, including targeted treatment, CAR-T-cell therapy, and immunotherapy, are being explored.
Review
Oncology
Verane Achard, Paul Martin Putora, Aurelius Omlin, Thomas Zilli, Stefanie Fischer
Summary: Metastatic prostate cancer treatment has shifted with the introduction of novel therapeutic agents, requiring clinicians to choose the most appropriate treatment combination and sequence for each patient based on individual factors to optimize efficacy.